Added to YB: 2025-10-28
Pitch date: 2025-10-24
PTGX [bullish]
Protagonist Therapeutics, Inc.
+10.59%
current return
Author Info
Ridire Research is an independent equity research platform focused on actionable, high-conviction long/short equity ideas. We combine fundamental rigor with quantitative structure to identify mispriced opportunities others overlook. Sign up for the newsletter.
Company Info
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
Market Cap
$5.2B
Pitch Price
$75.13
Price Target
N/A
Dividend
N/A
EV/EBITDA
197.54
P/E
114.49
EV/Sales
21.45
Sector
Biotechnology
Category
growth
Protagonist Therapeutics (PTGX) — Peptides Become Products
PTGX: Lead drug rusfertide hit Phase 3 in polycythemia vera, has Breakthrough/Orphan designations, launching via Takeda partnership within 2 years. Proprietary peptide platform creates defensible moat in rare diseases. Risks: regulatory timing, partner dependence, competition.
Read full article (3 min)